PAP
SUPN icon

Persistent Asset Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Persistent Asset Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,159
Closed -$247K – 448
2025
Q3 		$247K Buy
+5,159
New +$208K 0.17% 121

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Persistent Asset Partners's SUPN Position: Q4 2025 in Review

Persistent Asset Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 5,159 shares — an estimated $247K sold.

Persistent Asset Partners first reported a position in SUPN in Q3 2025 and held it in 1 quarter. The position peaked at $247K in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • Persistent Asset Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 5,159 Supernus Pharmaceuticals shares in Q4 2025, an estimated $247K.
  • Persistent Asset Partners first reported a position in Supernus Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Supernus Pharmaceuticals position peaked at $247K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.